Radioimmunodetection_of_neuroblastoma_with_iodine-131-3F8:_correlation_with_biopsy,_iodine-131-metaiodobenzylguanidine_and_standard_diagnostic_modalities._Iodine-131-3F8,_a_murine_IgG3_monoclonal_antibody_specific_for_ganglioside_GD2_was_evaluated_by_radioimmunoscintigraphy_in_42_patients_with_neuroblastoma._Comparison_was_made_with_131I-metaiodobenzylguanidine_(MIBG),_99mTc-methylene_diphosphonate_(MDP)_bone_scans,_as_well_as_computed_axial_tomography_(CT)_or_magnetic_resonance_imaging_(MRI)._Iodine-131-3F8_detected_more_abnormal_sites_(283)_than_131I_MIBG_(138)_or_99mTc-MDP_(69),_especially_in_patients_with_extensive_disease._In_20_patients_with_soft-tissue_tumors_demonstrated_by_CT/MRI,_131I-3F8_detected_the_disease_in_18._Upon_surgical_resection,_two_tumors_interpreted_as_negative_with_131I-3F8_imaging_revealed_ganglioneuroma,_one_showing_microscopic_foci_of_neuroblastoma._In_contrast,_131I-3F8_imaging_identified_tumors_that_were_confirmed_histologically_as_neuroblastomas._In_26_patients_with_evidence_of_marrow_disease_by_antibody_scans,_14/26_had_confirmation_by_iliac_crest_marrow_aspirate/biopsy_examinations._We_conclude_that_131I-3F8_scintigraphy_has_clinical_utility_in_the_management_of_patients_with_neuroblastoma_by_improving_the_sensitivity_of_tumor_detection.